TITLE

Aventis: New Giant on the Block

AUTHOR(S)
Alperowicz, Natasha
PUB. DATE
February 1999
SOURCE
Chemical Week;2/17/1999, Vol. 161 Issue 6, p55
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Provides information on Aventis, a combination of Hoechst's and Rhone-Poulenc's (RP) pharmaceutical, agricultural and veterinary businesses. Views of Igor Landau, president of RP and chairman designate of Aventis Pharma; Idea behind the merger; Total savings from the merger.
ACCESSION #
1579193

 

Related Articles

  • R&D Times Two. Stevens, Tim // Industry Week/IW;05/07/2001, Vol. 250 Issue 7, p49 

    Deals with the integration of research and development (R&D) departments of merging companies. Ways by which merging companies can help their R&D staff through the integration; Benefits of the R&D integration to Aventis, the company formed by the merger between Hoechst AG and Rhone-Poulenc SA;...

  • Aventis SA. Gee, Jack // Industry Week/IW;06/07/99, Vol. 248 Issue 11, p30 

    Presents information on the merger of Hoechst AG and Rhone-Poulenc SA. Details on Aventis SA, the life-sciences company which came out of the merger; Discussion on the plans for Aventis.

  • New Life-Science Giant Aventis To Overhaul R&D. Blau, John // Research Technology Management;Jan/Feb2000, Vol. 43 Issue 1, p4 

    Reports on the creation of Aventis SA, a company created from the merger of Hoechst AG and Rhone-Poulenc SA. Number of employees of the company; Total volume of sales of the company; Projected savings the companies will get from their merger; Goal of the merger.

  • Hoechst Shareholders Obtain Aventis Stock.  // Chemical Market Reporter;12/06/99, Vol. 256 Issue 23, p6 

    Deals with the negotiations made on the merger between Hoechst and Rhone-Poulenc. Plan of the companies to create the life sciences company Aventis; Trading of Aventis shares in the stock exchanges.

  • Aventis draws praise from analysts. Mirasol, Feliza // Chemical Market Reporter;12/14/98, Vol. 254 Issue 24, p10 

    Highlights analysts' views on Aventis, the life sciences company created by Hoechst AG and Rhone-Poulenc SA. Research and development budget for Aventis; Aventis' need to strengthen its operations to post the high profits of other giant pharmaceutical manufacturers.

  • Drugs giant seeks global agency. Killgren, Lucy // Marketing Week;2/25/1999, Vol. 22 Issue 4, p12 

    Reports that pharmaceutical giant Aventis, formed by the merger of Rhone-Poulenc and Hoechst, is seeking a global advertising agency to create a worldwide campaign to launch its new name. Five agencies Aventis has talked to; Background information on products.

  • Hoechst, Rhone-Poulenc merge drugs and Life Sciences Operations. Milmo, Sean // Chemical Market Reporter;12/07/98, Vol. 254 Issue 23, p1 

    Reports on Hoechst AG and Rhone-Poulenc Inc.'s proposal to merge their life sciences operations into a new company that will be called Aventis. Divestment conditions that must be satisfied; Drop in the companies' share prices following their announcement of the proposed merger; Comments from...

  • Hoechst-RP Merger Enters Final Stages to Form Aventis. Hume, Claudia // Chemical Week;11/3/1999, Vol. 161 Issue 41, p23 

    Focuses on the merger of Hoechst and Rhone-Poulenc (RP) to form the life sciences firm Aventis. Shares to be received by Hoechst shareholders; Headquarter relocation of RP; Plans for Aventis.

  • Hoechst, R-P Hammer Out Merger Details. Milmo, Sean // Chemical Market Reporter;05/24/99, Vol. 255 Issue 21, p7 

    Focuses on the merger agreement between Hoechst AG and Rhone-Poulenc Inc. Terms of agreement; Information on Avertis, life science business formed by the merger deal; Comment from Klaus-Juergen Schmieder, chief financial officer of Hoechst.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics